When comparing LF5 results (expression of cell cycle genes and TP53 mutations) with previous studies, they resembled those found in the molecular proliferative subgroup of ccRCC patients reported by a previous study (Motzer et al, 2020), both of which associated with poor overall survival of patients. Here, TP53 is linked to nonpapillary renal cell carcinoma.